144 related articles for article (PubMed ID: 37657175)
1. Dendritic polymer-functionalized nanomedicine potentiates immunotherapy via lethal energy crisis-induced PD-L1 degradation.
Li X; Duan Z; Li Z; Gu L; Li Y; Gong Q; Gu Z; Luo K
Biomaterials; 2023 Nov; 302():122294. PubMed ID: 37657175
[TBL] [Abstract][Full Text] [Related]
2. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming the Tumor Microenvironment through Second-Near-Infrared-Window Photothermal Genome Editing of PD-L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy.
Tang H; Xu X; Chen Y; Xin H; Wan T; Li B; Pan H; Li D; Ping Y
Adv Mater; 2021 Mar; 33(12):e2006003. PubMed ID: 33538047
[TBL] [Abstract][Full Text] [Related]
4. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
5. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
6. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
7. Integrated Nanorod-Mediated PD-L1 Downregulation in Combination with Oxidative-Stress Immunogene Therapy against Cancer.
Wu S; Zhang J; Pan J; Bai S; Wang Z; Chen Y; Xu D; An Y; Liu C; Chu C; Dai Q; Jiang L; Lu Z; Liu G
Adv Healthc Mater; 2023 Jul; 12(17):e2300110. PubMed ID: 36773310
[TBL] [Abstract][Full Text] [Related]
8. Self-delivery photodynamic-hypoxia alleviating nanomedicine synergizes with anti-PD-L1 for cancer immunotherapy.
Feng X; Chen Z; Liu Z; Fu X; Song H; Zhang Q
Int J Pharm; 2023 May; 639():122970. PubMed ID: 37084832
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-L1 DNAzyme Loaded Photothermal Mn
Liu P; Shi X; Peng Y; Hu J; Ding J; Zhou W
Adv Healthc Mater; 2022 Apr; 11(8):e2102315. PubMed ID: 34841741
[TBL] [Abstract][Full Text] [Related]
10. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer.
Li L; Wang J; Radford DC; Kopeček J; Yang J
J Control Release; 2021 Apr; 332():652-659. PubMed ID: 33607175
[TBL] [Abstract][Full Text] [Related]
12. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
14. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
Zhang R; Yang Y; Dong W; Lin M; He J; Zhang X; Tian T; Yang Y; Chen K; Lei QY; Zhang S; Xu Y; Lv L
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35181605
[TBL] [Abstract][Full Text] [Related]
15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
16. Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy.
Wang Y; Zhou SK; Wang Y; Lu ZD; Zhang Y; Xu CF; Wang J
Nat Commun; 2023 Apr; 14(1):1993. PubMed ID: 37031188
[TBL] [Abstract][Full Text] [Related]
17. Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.
Li JH; Huang LJ; Zhou HL; Shan YM; Chen FM; Lehto VP; Xu WJ; Luo LQ; Yu HJ
Acta Pharmacol Sin; 2022 Nov; 43(11):2749-2758. PubMed ID: 35484402
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
[TBL] [Abstract][Full Text] [Related]
19. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of anti-PD-1/PD-L1 immunotherapy for osteosarcoma using an intelligent autophagy-controlling metal organic framework.
Ge YX; Zhang TW; Zhou L; Ding W; Liang HF; Hu ZC; Chen Q; Dong J; Xue FF; Yin XF; Jiang LB
Biomaterials; 2022 Mar; 282():121407. PubMed ID: 35217343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]